[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100614920":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":21,"centralContacts":25,"locations":33,"responsibleParty":50,"collaborators":53,"id":57,"slug":20,"hasResults":58,"nctId":59,"briefTitle":60,"officialTitle":61,"acronym":20,"eligibilityCriteria":62,"healthyVolunteers":63,"sex":64,"minAge":65,"maxAge":66,"enrollmentInfo":67,"targetDuration":20,"studyType":70,"phases":71,"briefSummary":73,"conditions":74,"keywords":77,"overallStatus":36,"whyStopped":20,"lastUpdateSubmitDate":80,"lastUpdatePostDateStruct":81,"startDateStruct":84,"completionDateStruct":86,"leadSponsor":88,"locationsCount":89},{"fullName":5,"class":6},"Mayo Clinic","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Healthy Participants","EXPERIMENTAL","Healthy participants without pancreatic disease who are undergoing an endoscopic ultrasound for a non-pancreatic indication. This arm will be stratified into 3 age groups: 18-35, 35-45, and 46+ years. Participants will be given a standard dose of intravenous human secretin (0.2 mcg\u002Fkg) during the endoscopic ultrasound. During this time, pancreatic fluid will be collected at 5 minutes, 10 minutes, 15 minutes, and 20 minutes after secretin administration.",[13],"Drug: Secretin (human synthetic) - ChiRhoClin",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"DRUG","Secretin (human synthetic) - ChiRhoClin","During endoscopic ultrasound (EUS), a dose of intravenous secretin (0.2 µg\u002Fkg) will be administered over the course of 1 minute to stimulate pancreatic ductal cells to secrete pancreas fluid.\n\nDuodenal fluid will be aspirated through the echoendoscope in 5 minute increments (5, 10, 15, and 20 minutes) after the secretin has been administered",[9],null,[22],{"name":23,"affiliation":5,"role":24},"Samuel Han, MD","PRINCIPAL_INVESTIGATOR",[26,31],{"name":27,"role":28,"phone":29,"phoneExt":20,"email":30},"Liz Lemke","CONTACT","507-266-3317","Lemke.Elizabeth@mayo.edu",{"name":23,"role":28,"phone":20,"phoneExt":20,"email":32},"han.samuel@mayo.edu",[34],{"facility":35,"status":36,"city":37,"state":38,"zip":39,"country":40,"cosmosGeoPoint":41,"geoPoint":46,"contacts":47},"Mayo Clinic in Rochester","RECRUITING","Rochester","Minnesota","55905","United States",{"type":42,"coordinates":43},"Point",[44,45],-92.4699,44.02163,{"lat":45,"lon":44},[48,49],{"name":27,"role":28,"phone":29,"phoneExt":20,"email":20},{"name":23,"role":24,"phone":20,"phoneExt":20,"email":20},{"type":24,"investigatorFullName":51,"investigatorTitle":52,"investigatorAffiliation":5,"oldNameTitle":20,"oldOrganization":20},"Samuel Han","Principal Investigator",[54],{"name":55,"class":56},"ChiRhoClin, Inc.","INDUSTRY","100614920",false,"NCT07285863","A Study Of Effect Of Secretin For In Injection (Chirostim) On Pancreatic Fluid Composition In Healthy Subjects","An Open-Label Study On The Effects Of Human Secretin For Injection (CHIROSTIM) On Pancreatic Fluid Composition In Normal Human Volunteer Participants","Inclusion Criteria\n\n* Males or non-pregnant females\n* Age 18-80.\n* Participants must be in good health based on medical history (ASA Class 3 or below)\n* Participants must be willing and able to provide informed consent\n* Receiving an endoscopic ultrasound for a non-pancreatic indication\n\nExclusion Criteria\n\n* History of any form of pancreatitis and\u002For other pancreatic diseases (e.g. pancreatic cysts, pancreatic masses).\n* History of inflammatory bowel disease\n* History of vagotomy.\n* History of surgically altered upper gastrointestinal anatomy (e.g. gastric bypass, Billroth I\u002FII)\n* History of liver disease\n* Pregnant women or nursing mothers\n* Regular use of anticholinergics\n* \\> 2 drinks of alcohol daily\n* Smokers (cigarette)",true,"ALL","18 Years","80 Years",{"count":68,"type":69},24,"ESTIMATED","INTERVENTIONAL",[72],"PHASE4","The purpose of this study is to collect pancreas fluid from the duodenum using the endoscopic pancreas function collection method in healthy participants after pancreatic stimulation with human secretin.",[75,76],"Exocrine Pancreatic Insufficiency","Chronic Pancreatitis",[78,79],"pancreatic function test","Pancreatic fluid composition","2026-04-27",{"date":82,"type":83},"2026-04-28","ACTUAL",{"date":85,"type":83},"2026-03-11",{"date":87,"type":69},"2028-03",{"name":5,"class":6},1]